Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Proteomics International Laboratories Ltd (ASX:PIQ)
ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.150 -0.375 (-71.43%)+
Release
24 Dec 2025 10:15AM
Price at Release
$0.525
Full Release
Summary
Proteomics International Laboratories Ltd (ASX: PIQ) announced that its US Reference Laboratory in Irvine, California, has received accreditation from the College of American Pathologists (CAP), a prestigious recognition in the field of laboratory quality. This accreditation complements their existing Clinical Laboratory Improvement Amendment (CLIA) certification. The CAP accreditation is expected to enhance patient outcomes by ensuring rigorous laboratory standards. Additionally, the company has installed a new mass spectrometry platform to support the commercialization of their Promarker suite of precision diagnostic blood tests, including PromarkerEso for esophageal cancer and PromarkerEndo for endometriosis. The accreditation and technological advancements position Proteomics International as a leading provider of quality precision diagnostics, with plans to launch new tests in the US by 2026.
Key Points
- US Reference Laboratory accredited by College of American Pathologists (CAP).
- CAP accreditation recognized for rigorous standards, enhancing patient outcomes.
- New mass spectrometry platform installed for Promarker diagnostic blood tests.
- PromarkerEso test for esophageal cancer to launch in the USA in 2026.
- Existing CLIA certification complemented by CAP accreditation.
- Proteomics International positioned as leading provider of precision diagnostics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
